Mercer Global Advisors
APGE icon

Mercer Global Advisors’s Apogee Therapeutics APGE Stock Holding History

Mercer Global Advisors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70M Sell
831,428
-59,237
-7% -$4.3M 0.1% 115
2025
Q4 		$67.2M Sell
890,665
-79,916
-8% -$5.03M 0.1% 122
2025
Q3 		$38.6M Buy
970,581
+150,205
+18% +$5.74M 0.06% 182
2025
Q2 		$35.6M Sell
820,376
-819,804
-50% -$31.2M 0.07% 154
2025
Q1 		$61.3M Buy
1,640,180
+920,079
+128% +$35.6M 0.14% 87
2024
Q4 		$32.6M Buy
+720,101
New +$36.7M 0.08% 138

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Mercer Global Advisors's APGE Position: Q1 2026 in Review

Mercer Global Advisors reduced its Apogee Therapeutics (APGE) stake by 6.7% in Q1 2026, selling an estimated $4.3M and leaving 831,428 shares worth $70M. The position accounts for 0.1% of the portfolio, ranked #115.

Mercer Global Advisors first reported a position in APGE in Q4 2024 and has held it in 6 quarters since. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Mercer Global Advisors held 831,428 shares of Apogee Therapeutics worth $70M as of Q1 2026.
  • Mercer Global Advisors sold 59,237 Apogee Therapeutics shares in Q1 2026, an estimated $4.3M.
  • Apogee Therapeutics made up 0.1% of Mercer Global Advisors's portfolio in Q1 2026, its #115 holding.
  • Mercer Global Advisors first reported a position in Apogee Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.